CD19 CAR T cell product and disease attributes predict leukemia remission durability

BACKGROUND. Chimeric antigen receptor (CAR) T cells can induce remission in highly refractory leukemia and lymphoma subjects, yet the parameters for achieving sustained relapse-free survival are not fully delineated. METHODS. We analyzed 43 pediatric and young adult subjects participating in a phase...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Main Authors: Finney, Olivia C., Brakke, Hannah, Rawlings-Rhea, Stephanie, Hicks, Roxana, Doolittle, Danielle, Lopez, Marisa, Futrell, Ben, Orentas, Rimas J., Li, Daniel, Gardner, Rebecca, Jensen, Michael C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2019
Assuntos:
Clinical Medicine
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6486329/
https://ncbi.nlm.nih.gov/pubmed/30860496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI125423
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares